Particle.news
Download on the App Store
6 ARTICLES
·
last wk.

COVID-19 Boosters Cut Severe Outcomes by Nearly 30% in Cancer Patients

Low bivalent booster uptake, at just 38 percent, has prompted researchers to extend real-world evaluations to other vulnerable populations.

Image

Overview

  • A retrospective study published July 17 in JAMA Oncology found that both monovalent and bivalent boosters reduced hospitalization and ICU admission risk by 29 percent among cancer patients.
  • Investigators analyzed health records for more than 161,000 adults treated for cancer across four major U.S. health systems.
  • Boosters prevented one hospitalization or ICU admission for every 150 to 166 recipients, with the monovalent vaccine showing a lower number needed to vaccinate than the bivalent formulation.
  • Booster coverage was suboptimal, with 68 percent of eligible patients receiving monovalent doses and just 38 percent receiving updated bivalent shots.
  • The research team is now preparing similar analyses in patients with autoimmune disorders and organ transplants to inform future vaccine guidance.